Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Closes IPO Raising $184M

NEW YORK (GenomeWeb News) – Intrexon announced after the close of the market on Tuesday the closing of its initial public offering raising $184 million in gross proceeds.

The Germantown, Md.-based synthetic biology firm said it sold about 11.5 million shares of its common stock at $16 per share. About 10 million shares were sold as part of the initial offering, and another 1.5 million shares were sold to the underwriters of the offering as part of their overallotment option.

JP Morgan and Barclays were joint book-running managers on the offering. Griffin Securities and Mizuho Securities were co-managers.

Intrexon went public on Aug. 8.

In morning trading on the New York Stock Exchange, shares of Intrexon were down 6 percent at $27.03

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.